The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction

Published

Journal Article

Fifty-four patients with advanced epithelial ovarian cancer were monitored with serial serum CA 125 levels after surgical cytoreduction and during multi-agent chemotherapy with cisplatin-containing regimens. CA 125 half-life of <20 days was associated with prolonged overall survival (p < 0.015). In those patients who eventually were found to be disease-free at surgical surveillance procedures, normalization of serum CA 125 levels to <35 U/ml within 65 days of primary operation also suggested an improved survival (p < 0.059). © 1990.

Full Text

Duke Authors

Cited Authors

  • Hunter, VJ; Daly, L; Helms, M; Soper, JT; Berchuck, A; Clarke-Pearson, DL; Bast, RC

Published Date

  • January 1, 1990

Published In

Volume / Issue

  • 163 / 4 PART 1

Start / End Page

  • 1164 - 1167

International Standard Serial Number (ISSN)

  • 0002-9378

Digital Object Identifier (DOI)

  • 10.1016/0002-9378(90)90680-6

Citation Source

  • Scopus